Hans Christinger is Vice President of Business Development & Alliance Management at Ovid Therapeutics. Hans is a dedicated leader, innovator and advocate in the rare disease community with over 25 years of experience in the biopharmaceutical industry. At Ovid, Hans establishes and manages global strategic partnerships to rapidly bring potential therapeutics to patients and families affected by rare, neurological disorders, such as Ovid’s relationships with Takeda and Lundbeck. Hans is driven by hope and passion to increase awareness and advance a scientific understanding for members of the rare disease community. Hans plays a critical role in bringing together multiple stakeholders to efficiently address the unmet therapeutic needs within rare and neglected disease communities. Hans has led and executed numerous transactions for Ovid, Ophthotech, Abbott, Roche and Vertex. Having been based both in the US and abroad, he established and led teams to enable global, regional and local transactions across more than 30 countries in emerging and developed markets. Hans is an active board member and advisor to the KIF1A Foundation, NYBIO and several early-stage biotechnology companies. Hans began his career as a bench scientist at Genentech where he authored 15 structural biology related peer-reviewed papers. He earned a Master of Business Administration from Babson College, a Master of Science in Chemistry from San Francisco State University and a Bachelor of Science in Biochemistry from the University of Vermont.